Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00063206|
Recruitment Status : Completed
First Posted : June 25, 2003
Last Update Posted : August 19, 2009
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D<sub>17</sub>] < 7) versus those subjects receiving placebo.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: DVS-233 SR||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||247 participants|
|Official Title:||A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder|
|Actual Primary Completion Date :||May 2004|
|Actual Study Completion Date :||May 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00063206
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|